Title: Transition to Inspections: USP<823>, 21 CFR 212, And Beyond?
1Transition to InspectionsUSPlt823gt, 21 CFR 212,
And Beyond?
- Panel Discussion
- Ravi S. Harapanhalli, Ph.D
- Louis Marzella, MD
- Ravindra Kasliwal, Ph.D
- Wendy Sanhai, Ph.D.
2Topics
- PET Regulatory framework
- GMPs and FDAs jurisdictions
- Salient features of 21 CFR 212
- Questions and answers
3GMPs Simplified
If it is not documented, it does not exist!
4Quality Systems Approach to Inspections
5FDA Retains Authority to Inspect Research PET
drugs and INDs
- Although USP Chapter lt823gt, rather than part 212,
constitutes the minimum CGMP requirements for
investigational and research PET drugs, FDA
retains the authority to inspect facilities where
investigational and research PET drugs are
produced to verify compliance with either Chapter
lt823gt or part 212.
6FDAs Regulatory Framework for PET
Radiopharmaceuticals
- Radiopharmaceutical INDs (21CFR312)
- Exploratory INDs, Traditional INDs
- cGMPs for INDs (USPlt823gt)
- RDRC imaging studies (21CFR361)
- PET Radiopharmaceutical NDAs (21CFR314)
- Predetermined to be safe and effective
- FDG F 18 Injection, Ammonia N 13 Injection,
- Sodium Fluoride F 18 Injection
- Novel PET agents
- PET cGMPs for NDAs/ANDAs (21CFR212)
- PET Radiopharmaceutical Drug Master Files (21CFR
314.420) - Radionuclide production
- Precursors and Final intermediates
- Automated radiosynthesis units
7GMPs for INDs and NDAs
- FDC Act 501(a)(2)(B)
- cGMP requirement for all drugs including INDs
- Incremental approach during IND stages
- Enforcement discretion
- 21 CFR 210/211 requirements
- Commercial manufacture
- Phase 2/3 drugs
- Not for Phase 1 INDs (Phase 1 IND guidace to be
followed) - 21 CFR 212 requirements
- NDA and ANDAs for PET radiopharmaceuticals
- Not for other radiopharmaceuticals
- May be followed for INDs in lieu of USPlt823gt
8Guidance on PET Drug Product Submissions
- PET Drug Products Safety and Effectiveness of
Certain PET Drugs for Specific Indications - FR March 10, 2000 (Volume 65, Number 48), Pages
12999-13010. - Draft Guidance on the Content and Format of
NDAs/ANDAs for Certain PET Drug Products - FR March 10, 2000 (Volume 65, Number 48), Pages
13010-13012. - FDG F 18 Injection, Ammonia N 13 Injection
- Sodium Fluoride F 18 Injection
- CMC section for the three radiopharmaceuticals
may be formatted as described in the draft sample
formats. - Other new PET drugs should follow the ICH Common
Technical Document (CTD) format
9Clarity provided in the Final PET Rule
- 212.70(f) Conditional final release
- Conditional release due to equipment breakdown or
malfunction? Yes - Include problems related to but not specifically
due to actual equipment breakdowns? May be - delete the notification requirements? No
- any circumstance under which conditional release
would not be permitted even if the release
criteria were met? E.g. radiochemical ID, RCP,
specific activity? No - 212.70(e) Sterility testing
- Can justify a post-manufacture wait time beyond
24-30 h? Yes
10Pre-release Endotoxin Testing Requirement
- USP lt823gt mandates it for radionuclides with t1/2
gt 20.0 - May be difficult for certain C 11 PET drugs.
- Requiring a rapid endotoxin testing (20 min test)
from kits currently made by only one company may
not be appropriate - 212 Requirements
- The product can be distributed under control
after a pharmacopeial bacterial endotoxin test is
initiated. However, the endotoxin results should
meet the acceptance criteria before administering
the product to humans.
11A Science and Risk based Approach for Endotoxin
Testing
- Good manufacturing history and GMP compliance
- Good record of endotoxin test results
- Before hot synthesis, a cold synthesis run with
endotoxin monitoring to confirm acceptable
endotoxin levels in the product. - A commitment to initiate endotoxin testing as
soon as practicable and to convey the results of
the testing to the physicians on a real-time
basis (but before patient administration??) - A requirement in place to retain the patients
until the endotoxin results are obtained. - A safety monitoring provision in the clinical
study protocol for any endotoxin-related events
12Final release of PET Product (Â 212.70(c) ) and
Appropriate Laboratory Determination
- An appropriate laboratory determination is
required to ensure that each batch of a PET drug
product conforms to specifications, - Is a finished-product testing of each batch a
must? Not if . - Alternative validated QbD and PAT-based criteria
are used in lieu of end testing - In-process testing of an attribute that is
equivalent to finished-product testing of that
attribute - Continuous process monitoring of attributes with
statistical process controls and ability to
adjust the process - Some combination of these approaches
13Handling Non-critical Quality Attributes
- Radionuclidic purity if potential radionuclidic
impurities have a low risk of impacting safety
and/or effectiveness - Certain low-level nontoxic impurities
- Class 3 residual solvents
- Periodic Quality Indicator Tests permitted
- Formerly called as skip-lot testing
- Contingent upon use of a process that is under a
state of control - Testing in addition to specification testing
- Method and limits should be established in an
application - Frequency of testing will be determined during
cGMP inspections - Can be handled and refined by internal quality
systems
14Significance of Process Verification
- Section 212.50(f)(1) PET drug production in
which every batch undergoes full finished-product
testing, process verification is not required. - Section 212.50(f)(2) requires process
verification when - the results of the production of an entire batch
of a PET drug are not fully verified through
finished-product testing - only the initial sub-batch in a series is tested
- E.g. N-13 ammonia, alternative laboratory
determinations, PQIT
15Critical Components of Process Capability
Centering and Spread
16Some Questions
- 212 says that final product vial assembly and
sterility testing should be done under Class 100
area. Should the PET dose drawings from finished
product vial be done under Class 100 hood? - What if radiation dose inhibits microbial growth
when spiked drug product is kept for gt 30 h?